RT Journal Article
SR Electronic
T1 Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20187112
DO 10.1101/2020.09.03.20187112
A1 Cruz, Leticia R.
A1 Baladrón, Idania
A1 Rittoles, Aliusha
A1 Díaz, Pablo A.
A1 Valenzuela, Carmen
A1 Santana, Raúl
A1 Vázquez, Maria M.
A1 García, Ariadna
A1 Chacón, Deyli
A1 Thompson, Delvin
A1 Perera, Gustavo
A1 González, Ariel
A1 Reyes, Rafael
A1 Torres, Loida
A1 Pérez, Jesus
A1 Valido, Yania
A1 Rodriguez, Ralysmay
A1 Vázquez, Dania M.
A1 Rosales, Mauro
A1 Ramón, Ailyn C.
A1 Pérez, George V.
A1 Guillén, Gerardo
A1 Muzio, Verena
A1 Perera, Yasser
A1 Perea, Silvio E.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/09/22/2020.09.03.20187112.abstract
AB Purpose The instrumental role of CK2 in the SARS-Cov2 infection has pointed out this protein kinase as a promising therapeutic target in Covid-19. Anti-SARS-Cov2 activity has been reported by CK2 inhibitors in vitro; however, any anti-CK2 clinical approach has been investigated in Covid-19. This exploratory trial aimed to explore safety and putative clinical benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer.Methods A monocentric, parallel group design, therapeutic exploratory trial of intravenous CIGB-325 in adults hospitalized with Covid-19 was performed. Twenty patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-consecutive days) plus standard-of-care (10 patients) or standard-of-care (10 patients). Adverse events were classified by the WHO Adverse Reaction Terminology. Parametric and non-parametric statistical analyses were performed according to the type of variable. Considering the small sample size, differences between groups were estimated by Bayesian analysis.Findings CIGB-325 induced transient mild and/or moderate adverse events like pruritus, flushing and rash in some patients. Both therapeutic regimens were similar respect to SARS-Cov2 clearance in nasopharynx swabs over the time. However, CIGB-325 significantly reduced the median number of pulmonary lesions (9.5 to 5.5, p = 0.042) at day 7 and proportion of patients with such effect was also higher according to Bayesian analysis (pDif > 0; 0.951). Additionally, CIGB-325 significantly reduced the CPK (p = 0.007) and LDH (p = 0.028) plasma levels at day 7.Implications Our preliminary findings suggest that this anti-CK2 clinical approach could be combined with standard-of-care in Covid-19 thus warranting larger studies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIG/CIGB300I/CV/2001Funding StatementThis work was supported in part by the British Embassy in Havana with funds of the International Programme of the Foreign, Commonwealth and Development Office (FCDO).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee for Clinical Research in the Luis Diaz Soto Hospital and Cuban Regulatory Agency (CECMED) approved the trial. The study complied with the Good Clinical Practices and the precepts established in the Declaration of the Helsinki World Medical Association. All patients met the inclusion criteria described in the protocol and signed the informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred in the manuscript is available.